All immunoassays for female serum testosterone give falsely high results in some samples. The effect is variable and cannot be predicted for any given sample. Inaccurate calibration or interference by cross-reacting substances is almost certainly the cause of the problem, but for many immunoassays, the exact nature of the interferent is not known. Some of the interference can be removed by employing an extraction step prior to immunoassay. The advent of fast simple and sensitive liquid chromatography tandem mass spectrometry methods offers an exciting alternative to immunoassay for serum testosterone measurement. It is recommended that all high serum testosterone concentrations in women are checked, before reporting, by a method which is accurate (i.e. minimal bias to isotope dilution gas chromatography mass spectrometry [ID-GCMS] method) and is not subject to interference. Action should also be taken by assay users, manufacturers, regulators and professional bodies to ensure accurate standardization and comparability of assays. Ann Clin Biochem 2007; 44: 5-15 
Introduction
Testosterone is the steroid hormone principally responsible for the development of secondary sex characteristics in men. Like all steroid hormones, testosterone stimulates the synthesis of speci¢c proteins by crossing the cell membrane and binding with a receptor in the nucleus, activating particular genes.
In women, who have much lower circulating serum testosterone concentrations than men, the adrenal cortex is responsible for 50% of production. The remainder is produced from the interstitial cells located in the ovarian stroma and from peripheral conversion. In men, over 90% of circulating serum testosterone is secreted directly from the Leydig cells in the testes on stimulation by luteinizing hormone (LH). The remaining 10% comes from peripheral conversion of precursors secreted from the zona reticularis of the adrenal cortex. The testosterone circulating in blood is mostly bound to sex hormone binding globulin (SHBG) or albumin with only about 1% unbound in female plasma. It has been considered that the free hormone is the metabolically active fraction able to diffuse across cell membranes and interact with receptors and exert a feedback e¡ect. However, for many years, it has been suggested that the albumin and even the SHBG-bound fraction may also be biologically active. 1, 2 Serum testosterone measurement is often requested in female patients, most commonly for the investigation of hirsutism/amenorrhoea. Most of these patients will have polycystic ovary syndrome (PCOS) or idiopathic hirsutism. 3 However, a few will have a more serious pathology (adrenal/ovarian tumours, Cushing's syndrome or late-onset congenital adrenal hyperplasia). Previously it has been shown that the likelihood of serious pathology is low, if the serum testosterone measured after sample extraction is less than 5 nmol/L. 4 In most laboratories in the UK, measurement of total testosterone and/or SHBG is o¡ered in the initial investigation of women with a possible androgenic disorder. Many laboratories also calculate the Free Androgen Index (serum testosterone Â100/SHBG) (FAI). This has been shown in some studies to be a more sensitive marker of PCOS, 5, 6 although its accuracy in predicting free testosterone concentration has been questioned. 7 Measurements of free testosterone have been performed using equilibrium dialysis techniques but, being technically complex, these are not suitable for use in most laboratories. A direct radioimmunoassay (RIA) for free testosterone has been developed but has been shown r 2007 The Association for Clinical Biochemistry not to be a reliable indicator of free testosterone concentration. 7, 8 Several methods have also been proposed for the calculation of free testosterone in plasma using the total testosterone, SHBG and sometimes serum albumin concentration. These have been shown in general to be reliable indicators of free testosterone concentration. 7--9 Measurement of the 'bioavailable' or non-SHBG-bound testosterone has also been described. 10 This technique usually involves precipitation with ammonium sulphate to remove the SHBGbound fraction. This is followed by either measurement of testosterone in the supernatant 11 or by addition of a tracer amount of tritiated testosterone to the serum and determination of the radioactivity in the supernatant. 12 Again this measurement has been advocated as a more reliable indicator of free testosterone concentration than the FAI, 7,12 but due to its technical complexity is not in routine use in UK laboratories.
Other androgens (androstenedione, dehydroepiandrosterone [DHEA] sulphate) and 17-hydroxyprogesterone are sometimes measured in patients with raised concentrations of serum testosterone and/or FAI in order to help in di¡erential diagnosis. Small increases in the serum testosterone concentration (3.0--4.0 nmol/L) and a raised FAI are relatively common and may indicate the presence of PCOS. The likelihood of a diagnosis of PCOS is increased if the androstenedione concentration is also raised. The presence of a serious pathology is unlikely if the serum testosterone, measured using an extracted immunoassay, is o5.0 nmol/L. If the serum testosterone concentration is high (45.0 nmol/L), raised androstenedione and DHEA sulphate concentrations suggest adrenal involvement, whereas the presence of increased androstenedione and normal DHEA sulphate suggests ovarian pathology. The presence of an increased 17-hydroxyprogesterone concentration suggests a diagnosis of late onset congenital adrenal hyperplasia. Although PCOS is still a possible diagnosis in patients with serum testosterone concentrations 45.0 nmol/L, there is a greater likelihood of serious pathology being present (including malignant tumours). Further tests (adrenal/ovarian scan) may be indicated and the patients should be referred to a clinical endocrinologist for further investigation.
It is well recognized that some female samples give falsely high results when measured in direct (nonextracted) testosterone immunoassays. Recently, Taieb et al. reported on the measurement of female serum testosterone using 10 immunoassays compared with isotope dilution gas chromatography mass spectrometry (ID-GCMS). They concluded that none of the assays was suitable for the measurement of female serum testosterone, with most showing large positive bias to the reference method. 13 In an editorial commenting on this paper, Herold and Fitzgerald suggested for many current immunoassays, which miss the target by 200--500%, that guessing the result would be a better alternative and 'could provide cheaper and faster testosterone results for women without even having to draw the patient's blood'. 14 Recently, Wang et al. 15 in an article comparing the measurement of serum testosterone in men by immunoassay and liquid chromatography tandem mass spectrometry (LC-MS/MS) also concluded that, due to poor precision and accuracy at testosterone concentrations less than 3.5 nmol/L, current assays were not suitable for measurement of serum testosterone in women.
State of the art of present immunoassays for serum testosterone (female range)
Trueness (accuracy) as indicated by EQA bias and reference method studies It can be seen that the two major methods --Bayer Advia Centaur and Roche Elecsys/E170 Modular --and two subsidiary methods --Beckman Access and DPC Immulite 2000 --all have similar bias. Other minor methods have distinctly di¡erent bias characteristics. All groups have some variability about the median with interquartile ranges of around 10--15%. Not shown on the ¢gure is the emerging tandem mass spectrometry method group (4 users), which had a mean bias of À30% at June 2006.
But which (if any) of these methods gives the 'true' result and why is comparability between methods so poor? Steroid hormones are de¢ned chemical entities, which can be obtained 'o¡ the shelf' 99% pure. Standard solutions with very low uncertainty of assigned values may therefore be prepared. Furthermore, reference methods have been available for decades, 14 which enable the content of serum calibrants and controls to be established with minimal error. Networks of steroid reference laboratories also exist 15 whose members exchange protocols and results so as to maintain a trueness base (established using a panel of unprocessed single donation human sera whose testosterone values have been assigned by the reference laboratories). The newly formed Joint Committee for Traceability in Laboratory Medicine (JCTLM) 16 is compiling a database of reference methods and reference materials, which can be used to assign values to calibrants and controls Ann Clin Biochem 2007; 44: [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] and thus meet the traceability requirements of the European Union In Vitro Diagnostic Devices (EU IVD) Directive. 17 Materials and methods for steroid hormones were among the ¢rst to be included in the JCTLM database. All assays should, therefore, be accurately calibrated and their relationship with the reference method well established and understood. 18, 19 Figure 2 shows the results of male and female matrix recovery exercises undertaken by UK NEQAS in June 2006. Three pools were distributed for each matrix, a basal pool and two others spiked with doubling amounts of pure testosterone in ethanolic solution. The ¢gure shows that there is no correlation between mean method bias and recovery for the female matrix (r 2 ¼0.04) but a suggestion of a trend for the male matrix (r 2 ¼0.47). Recovery in the male matrix is superior to that in the female (except for tandem mass spectrometry where it was quantitative) and there are marked discrepancies between recovery in the two matrices for all methods except DPC Coat-a-Count and tandem mass spectrometry. It should be noted that the data shown are typical, stable characteristics of methods when recovery exercises are repeated annually. Since recovery of pure analyte is an important test of analytical validity, it is surprising that the poor recovery of testosterone in the female matrix has apparently been ignored by both manufacturers and laboratories.
The benchmark exercise is to distribute pools with reference method assigned values so as to enable true bias to be assessed. Figure 3 summarizes the data obtained by UK NEQAS in February 2005 using three unprocessed human serum pools which had reference method (ID-GCMS) values assigned by a steroid reference laboratory.
The ALTM was parallel to the y ¼ x line, but was o¡set by almost 1nmol, and the large range in results was evident. The di¡erence plot shows how great the bias is at low concentrations of testosterone, and that results may be up to 100% positively biased at the current presumed upper limit of normal. On analysis of the results for individual methods, problems with both speci¢city (scatter about the regression line and non-linearity at low concentrations) and calibration (slope signi¢cantly di¡erent from 1) were evident in varying degrees for all the automated platforms, including those that are allegedly calibrated using ID-GCMS value assigned materials. Only the manual RIA methods (DPC Coata-Count, Orion Spectria) and in-house extraction appeared to be more linearly comparable to the reference method (data available on request).
Specificity of testosterone immunoassays
As reported in the previous section, all the automated immunoassay methods for female testosterone su¡er from both calibration and speci¢city problems resulting in the production of falsely high serum testosterone concentrations compared to the reference method Figure 3 Comparison of female serum testosterone measured by immunoassay methods with results obtained using IDMS. The regression plot (a) shows the 5th, 25th, 50th, 75th and 95th percentiles of the results from all laboratories for three unprocessed human serum pools whose testosterone target value was determined by the Steroid Reference Laboratory at the University of Gent and given on the x-axis. The difference plot (b) shows the percentage bias (y-axis) of the same percentiles from the IDMS target value (x-axis) for these pools (ID-GCMS). Speci¢city problems seem to occur mainly in the direct assay of testosterone in female samples with better agreement being reported for most male samples. However, as discussed later in this article, there can still be problems with some low concentration male samples. Interference in female and low concentration male samples could be due to cross-reacting compounds being present both in men and women but being masked in normal men by the much greater concentrations of testosterone. To date, it is not known if the lack of speci¢city in testosterone immunoassays is due to an exogenous or endogenous source. However, the interfering substance or substances are known to be relatively insoluble in ether due to their being partially removed by an extraction procedure. This implies that the substance(s) must be more hydrophilic than hydrophobic. Due to their hydrophobic nature, steroid drugs (such as the oral contraceptive pill or co-cyprindol ['dianette'] --common in the treatment of PCOS) are unlikely to be the cause of the interference. However, any of their water-soluble metabolites would have the potential to interfere in the assay. It has recently been reported that in one commercially available assay there is signi¢cant cross-reactivity with DHEA sulphate, which would explain the high results obtained in some samples. 20 However, this may not be the explanation for false high results obtained using other immunoassay methods. Literature reviews 21, 22 describe interference in immunoassays by various compounds including serum proteins (e.g. rheumatoid factor, binding proteins, heterophilic and anti-animal antibodies, drugs and drug metabolites, haemolysis before processing broadly reactive antibodies [induced by Escherichia coli infection]), monoclonal IgM and plasma. However, studies relating speci¢cally to interference in serum testosterone assay in women are sparse. Substances implicated as causing interference are Danazol (a gonadotrophin inhibitor with androgenic and antioestrogenic properties) 23--25 and the abortifacient mifepristone (RU486). 26 A recent study has shown that the di¡erence between serum testosterone results obtained using direct and extracted assays was not related to the concentration of SHBG. In addition, the large positive bias in some samples was not due to assay imprecision or related to the source of the samples. 27 This still leaves the possibility that immunoglobulins, water-soluble drugs and drug metabolites, plasma proteins or endogenous steroids or steroid conjugates are causing interference in the assay.
A recent study 28 has evaluated the di¡erence in serum testosterone results in 1271 female samples measured by a direct immunoassay and after sample extraction into diethyl ether. All these samples had an initial (direct) testosterone concentration of 43.0 nmol/L. The median di¡erence (direct --extracted result) was 1.4 nmol/L (range À1.2--33.7) and the distribution was unimodal. The implication of this result is that the substance, causing the increase in measured testosterone in the direct assay, is present to a greater or lesser extent in all samples from women with a serum testosterone 43.0 nmol/L. In the authors' experience, there is still evidence of interfering substances at serum testosterone concentrations down to 2.4 nmol/ L. This result favours an endogenous source for the interference that is common to all women, with high serum testosterone concentrations. In our opinion, the presence of a bimodal distribution would have been consistent with a speci¢c drug, class of drugs or a speci¢c pathology causing the discrepancy in the assay results. Those taking the drug(s) or having the speci¢c pathology would show interference in the direct assay giving a high concentration peak. The remainder of the population would show very little or no interference. In one of the author's (JK) laboratories, approximately 25% of female samples have a direct testosterone 43.0 nmol/L and therefore require extraction. In approximately 50% of these samples, the extracted testosterone is subsequently normal. The proportion of female samples with a direct testosterone 4 3.0 nmol/L will obviously vary with the particular method employed.
The exact nature of interfering compounds in the various immunoassays for testosterone has, as yet, not been elucidated. However, it is probable that the interference is due to steroid conjugates, present in the serum of some patients, which react with testosterone antibodies in direct assays. These conjugates are watersoluble and are therefore not taken up by diethyl ether, allowing the sample to be partially cleaned up by a simple ether extraction procedure. As stated previously, DHEA sulphate has been implicated as a source of interference in one assay. 20 However, the cause of the high bias versus GCMS in other direct testosterone assays has not yet been elucidated. Discovering the source of the interference in testosterone immunoassays would solve a puzzling scienti¢c problem. Optimization of assays to remove interferences, in conjunction with the correction of calibration problems, would bring much bene¢t to patients and clinicians.
Solutions and recommendations for best routine practice Optimum use of direct immunoassay -in-house or in referral labs
As already discussed, the degree of interference in female serum testosterone measurement is not predictable in any given sample. This could potentially result in normal women having results suggestive of polycystic ovarian syndrome or a more serious condition such Ann Clin Biochem 2007; 44: [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] as an androgen-secreting tumour or late onset congenital adrenal hyperplasia. This could in turn potentially lead to unnecessary further investigations or procedures being performed on these patients.
Because of this problem, it is very important that high serum testosterone results on women are checked before release from the laboratory. This could either be done by referral of the sample for analysis by an external laboratory employing a more speci¢c (extraction) immunoassay or LC-MS/MS technique or by development 'in-house' of a suitable extraction procedure. What is de¢ned as a high result is open to some debate. As stated previously, it has been shown that the likelihood of serious pathology is low if the serum testosterone is less than 5 nmol/L, using an in-house extracted RIA. 4 However, the diagnosis of PCOS is often suspected if the serum testosterone is greater than 3.0 nmol/L. For this reason, in one of the author's (JK) laboratories, all female samples with a direct testosterone of greater than the reference range of the extracted assay (2.4 nmol/L) are re-assayed after an ether extraction step. Figure 4 gives an indication of the di¡erences in measured serum testosterone in female samples (with an initial testosterone concentration 43.0 nmol/L) between two commercially available testosterone immunoassays and by an in-house RIA involving an ether extraction procedure. 27 It can be seen that the serum testosterone concentrations measured on some samples di¡ered by a factor of up to 100%. However, this interference was not predictable and some samples gave very similar results with direct and extracted procedures. Similar results have recently been obtained with another commonly used commercial assay system. 29 A simple extraction procedure for serum testosterone on the Abbott Architect analyser employed in one of the author's (JK) laboratories is given in Appendix 1.
Use of extraction procedures
This method can be adapted simply for use on other immunoassay analysers. In the author's experience, the critical step is obtaining a suitable matrix from which the dried extract is drawn. This must be compatible with the matrix used in the standard curve on the instrument or incorrect results will be obtained. In many cases, a diluent can be provided by the kit manufacturer, although in the author's laboratory horse serum has been used as a suitable alternative. The testosterone concentration in the diluent should be measured in every batch and, if necessary, the results recalculated removing the baseline testosterone concentration of the diluent.
LC-MS/MS for serum testosterone measurement
In view of the increasing concern about the use of immunoassay for the measurement of serum testosterone at concentrations typically found in women, it has become necessary to consider alternative technologies which can be adapted to provide a routine clinical service. LC-MS/MS methods have the advantage of potentially high speci¢city without the need for the large sample volumes and lengthy sample preparation, including derivatization, required for the reference method, ID-GCMS. 13, 16, 30, 31 Published methods have appeared for the measurement of testosterone by LC-MS/MS since the 1980s but most have required large sample volumes 4750 mL, 13,32--34 Figure 4 Plot of the percentage difference in female serum testosterone measured in two commercially available direct immunoassays and by radioimmunoassay after sample extraction (% differences are plotted against the mean of the direct and extracted testosterone result) or online, 36 and lengthy chromatographic runs of greater than 10 min. 35, 36 However, a preliminary communication 37 recently outlined an assay that utilized 200 mL of serum extracted with methyl-tertiary butylether (1mL) containing deuterated testosterone as internal standard. After evaporating down the solvent, the residue is reconstituted in mobile phase (100 mL) and 50 mL injected onto the LC column. The cycle time from injection to injection is only 2 min and both testosterone and androstenedione can be measured in the same sample. The lower limit of quanti¢cation de¢ned as an imprecision of o20% and a bias of o15% is quoted as 0.25 nmol/L for testosterone. The female reference range of 0.27--1.56 nmol/L, n ¼ 99, is considerably lower than the range established by immunoassay (o0.5--2.4 nmol/L). This method appears to be feasible for providing a routine service for serum testosterone concentrations of 0.25 nmol/L and above. The Supraregional Assay Service (SAS) Centre for Steroid Hormones in Leeds has been using an LC-MS/ MS method 38 for all testosterone measurements for 21 months. An outline of the method is given in Appendix B. Comparison with in-house extraction RIA showed similar results to those previously reported, 13, 15, 39 but in addition it was found that some low concentration samples from men are even more discrepant than for women. Conversely, some samples from women with high serum testosterone concentrations, within the male reference interval, showed much better agreement than at the low concentrations, indicating that the problem might be, at least in part, poor speci¢city at low concentrations rather than a female matrix e¡ect. LC-MS/MS has proved to be a reliable and robust technique for measuring serum testosterone at concentrations of 0.3--100 nmol/L. A batch of 192 tubes, including calibrators, quality control samples and clinical samples takes about 2--3 h to set up, 17.5 h to run and a further 1--2 h to check the chromatograms for correct integration and recording batch details. All samples from children, women and men are measured by this procedure, partly because samples from men on replacement can often vary from low to high concentrations and we prefer not to quote results for the same patient using di¡erent assays (this is especially important in view of the large di¡erences in values by immunoassay versus LC-MS/MS); but also because the LC-MS/MS method is easier, better and more robust than the extraction RIA method previously employed. The routine batches are run by technical sta¡ who create the projects, prepare the samples, check the peak integration and also carry out routine maintenance such as cleaning the cone and draining the pump oil. However, LC-MS/MS is complex technology that requires expertise and experience. Tuning the instrument, method development and troubleshooting is carried out by senior clinical scientists, a considerable investment of resource by the department.
A recent paper by Kushnir et al. 40 describes a tandem mass spectrometry method for testosterone with a limit of quanti¢cation of 0.0346 nmol/L. Only 100 mL of serum or plasma is required, but sample preparation includes solvent extraction, derivatization and solidphase extraction prior to LC-MS/MS. However if there is a clinical need for the measurement of such low testosterone concentrations, e.g. in children, this report illustrates that the technology can meet the demand. The sample volume is still suitable for paediatric use but the more complex sample preparation necessitates a greater degree of technical ability and a lower sample throughput making it less suitable as a routine clinical assay.
LC-MS/MS technology is becoming suitable for use in routine clinical chemistry laboratories. For steroid analyses, it is necessary to purchase an MS/MS with adequate sensitivity. Currently, there are only two manufacturers who o¡er this and within their instrument series, a minimum of the Applied Biosystems instrument API 3000 or Waters/Micromass Quattro micro is required. The necessary equipment, including LC auto-sampler, tandem mass spectrometer and nitrogen generator, costs from $»170,000 upwards but a business case can be made for substituting the high cost of kits for commercial immunoassays by LC-MS/ MS with its minimal consumable costs. However, if there is a malfunction, it can be di⁄cult to identify the cause and the instrument can be out of use for longer than would occur with an immunoassay platform. Ideally more than one instrument is required if this technology is to be used for an urgent clinical service such as the measurement of 17a-hydroxyprogesterone for the diagnosis of 21-hydroxylase de¢ciency.
Analytical system specification and tendering by laboratories
It is critically important that laboratories specify parameters for trueness and traceability in their tender documents. Only by doing this en masse with other laboratories in a systematic way, might all manufacturers be encouraged to use the steroid reference measurement system to underpin the calibration of their assays.
Laboratories should request two graphs for each analyte:
(1) A regression plot of system result versus ID-GCMS target value for a series of single donation, unprocessed, patient sera with analyte concentrations across the range of clinical application and target values assigned by a member of the steroid reference laboratory network; and
(2) A di¡erence plot of the same data. The slope of the regression line will indicate overall trueness of calibration; the intercept will indicate degree of baseline security (the ability of an assay to detect low concentrations of analyte in the presence of possible interfering substances). The scatter (S yx ) about the regression line will indicate speci¢city and the shape of the di¡erence plot will indicate any concentrationrelated bias.
All manufacturers should be encouraged to employ the same materials in the same way and display their data in the same format for easy comparison between systems.
It is also imperative that laboratories emphasize to instrument producers that they need properly optimized assays for low testosterone concentrations encountered in most female samples and possibly, as discussed earlier in this article, some male samples with low testosterone concentration. The analytical problems associated with the measurement of testosterone in women clearly demand improved optimization, but this might adversely a¡ect the results of normal male samples, so a logical approach would be to create separately optimized immunoassays.
Recommended action by manufacturers and industry regulators
Manufacturers: Diagnostic companies should ensure that the reference measurement system is used to set assay calibration according to the full scienti¢c principles of metrological traceability. Manufacturers should collaborate together on the underpinning scienti¢c basis of assay standardization so that the customer can be assured that they are ful¢lling both the spirit and the letter of the IVD Directive and that the process is independent and scienti¢c.
Regulators: In the UK, the diagnostic industry is not regulated for trueness or traceability except through the EU IVDD. The Medicines and Healthcare Advisory Agency (MHRA) has a strong role as the Noti¢ed Body under the IVDD to monitor and take action where assay systems might cause patient harm. Trade organizations, e.g. the British In Vitro Diagnostics Association (BIVDA), have a role in ensuring that all its members sign up to and comply with the IVDD and could also be instrumental in encouraging cooperation and collaboration on the scienti¢c basis of standardization. In particular, BIVDA could help coordinate production of the single donation panels described above. This should be a collaborative exercise between all stakeholders: laboratories, EQA services, reference laboratories and manufacturers, with the latter accepting the major burden for funding of collection, value assignment and storage. The exemplar here would be the reference panel produced for cortisol in response to the Bergmeyer Conference. 41 Recommended action by professional bodies, accrediting organizations, government Professional bodies have strong educational and leadership roles in promulgating a thorough understanding of metrological traceability, and in helping clinicians and patients come to terms with revised analyte concentrations and normal values. This is particularly important in respect of the production of guidelines (e.g. national guideline for investigation of the infertile couple), 42 which have de¢ned analyte concentrations incorporated in them. The use of methods underpinned by or incorporating mass spectrometry technology may lead to a signi¢cant change in hormone concentrations, which are used in the assessment of patients. There will have to be re-education about the meaning of new reference values and guideline limits, but such issues are inevitable as the technology of measurement evolves.
Accrediting organizations generally assess quality systems, but analytical validity should be an integral part of quality assurance.
Government/Department of Health/National
Health Service must take great care to ensure that scientists with a detailed understanding of the relevant analytical and metrological issues are included in the advisory panels considering National Service Frameworks or Guidelines for investigation, screening and monitoring of treatment. The e¡ects of non-speci¢city, calibration and method variability must be estimated as part of an uncertainty budget around any hard numerical values that are recommended. It is also imperative that those involved in large-scale health-care computing and electronic patient record management also understand the e¡ect of variable assay bias on result comparability over geography and time.
Conclusions
This review has highlighted the problems in the measurement of female testosterone with all commercially available immunoassay methods giving incorrectly high results in some samples. The reasons for this are still unclear for most assays but certainly include inaccurate calibration in addition to the e¡ect of interfering substances. The degree of interference is not predictable in any given sample adding to the complexity of interpretation of the results.
At the very least, all high testosterone results in women should be checked using an alternative assay, preferably employing an extraction or chromatography step prior to immunoassay. However, even these steps do not completely remove substances with a potential to interfere in testosterone immunoassays.
Methods for testosterone employing LC-MS/MS have now been described which are suitable for providing a routine service for testosterone measurement. As shown in Figure 2 , this technique gives quantitative recovery of testosterone from a female matrix, whereas all immunoassays show low recovery of added testosterone. However, LC-MS/MS has a negative bias of 30% to the ALTM of immunoassay methods. These results imply that LC-MS/MS accurately measures testosterone in the sample and that adjustments have been made to the calibration of some immunoassays to compensate for poor speci¢city. LC-MS/MS is relatively complex and requires some expertise in operation but has the advantage of su¡ering from negligible interference from other steroids and steroid conjugates. Although obviously expensive to purchase in the ¢rst instance, these instruments have very low running costs so a case can be made to substitute expensive immunoassay kits with this new technology. Due to their speci¢city of measurement, the reference ranges obtained for testosterone in women by LC-MS/MS may be somewhat lower than those commonly in use at present. This will require re-education of those interpreting results but this is a small price to pay for the con¢dence that the testosterone result issued is a true measurement of that in the patient's serum. However, as many laboratories will still be performing immunoassay for female testosterone, it is important that action should be taken by assay users, manufacturers, regulators and professional bodies to ensure speci¢city, comparability and accurate standardization of assays. and a line plotted, by the LC-MS/MS software, of response against concentration. The plot is linear to at least 100 nmol/L. The cycle time between samples is 5.5 min. Intra-and inter-assay precision lies below 15% CV in the range 0.3--49 nmol/L and is below 10% CV at concentrations above 1nmol/L. Accuracy of the assay was demonstrated by comparison of values with three GCMS-targeted pools supplied by NEQAS and also by 20 pools with GCMS targets provided by Professor Cowan and his group at the Drug Control Centre, Kings College, London. The correlation for the 20 samples was r 2 ¼0.99 and the equation for the line y ¼ 0.96x þ 0.65. Recovery of testosterone added to serum samples at concentrations of 0.625--20 nmol/L was 96% with 11.7% CV, n ¼ 26. Extracted samples remain stable in the Eppendorf tubes for at least one week.
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